Sunitinib, sorafenib of no benefit in ECOG-ACRIN renal cell trial

Philadelphia, Pa., February 23, 2015, 5:00 PM– Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent® (sunitinib) or Nexavar® (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence...https://secure.kidneycancer.org/neon/resource/kca/files/ECOG-ACRIN_PressRelease_E2805_renal-cell-trial.pdf02/24/2015
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news